medigraphic.com
ISSN 1405-1710 (Print)

2022, Number 1-2

<< Back Next >>

Rev Cent Dermatol Pascua 2022; 31 (1-2)

Efficacy and safety of intralesional platelet-rich plasma compared with topical minoxidil 5% in the treatment of male androgenetic alopecia with vertex involvement

Hernández-Ramírez H, Zarate-Flores LM, Peralta-Pedrero ML, Medina-Bojórquez A, Jurado-Santa CF, Morales-Sánchez MA

Language: Spanish
References: 21
Page: 7-15
PDF size: 363.91 Kb.


ABSTRACT

Androgenetic alopecia (AGA) is the most common cause of hair loss in men with limited treatment options. Platelet Rich Plasma (PRP) therapy is one of the newer treatment options that has shown promising results. This study aimed to compare the clinical efficacy of PRP therapy versus minoxidil therapy. In the study, patients were randomized into two groups: Group 1 minoxidil and Group 2 platelet-rich plasma. Both groups were followed for a period of 12 weeks and the final analysis was carried out with the help of global and dermoscopic photography, DLQI questionnaire, satisfaction questionnaire and record of adverse events. A total of 60 patients with a clinical diagnosis of AGA were enrolled in the study with 30 patients in each group. At the end of 12 weeks, 60 patients were evaluated to compare the efficacy of intradermal PRP and topical minoxidil therapy. Regarding the content of hairs, no significant difference was found between the two groups. Side effects with PRP therapy were minimal with better results that may improve patient compliance. PRP therapy may be a valuable alternative to topical minoxidil therapy in the treatment of SAA.


REFERENCES

  1. Piraccini BM, Alessandrini A. Androgenetic alopecia. G Ital Dermatol Venereol. 2014; 149: 15-24.

  2. Gupta M, Mysore V. Classifications of patterned hair loss: a review. J Cutan Aesthet Surg. 2016; 9: 3-12.

  3. Alfonso M, Richter-Appelt H, Tosti A, Sanchez VMgarcía M. The psychosocial impact of hair loss among men: a multinational European study. Curr Med Res Opin. 2005; 21: 1829-1836.

  4. Kligman AM. The comparative histopathology of male-pattern baldness and senescent baldness. Clin Dermatol. 1988; 6: 108-118.

  5. Bayne EK, Flanagan J, Einstein M, Ayala J, Chang B, Azzolina B et al. Immunohistochemical localization of types 1 and 2 5alpha-reductase in human scalp. Br J Dermatol. 1999; 141: 481-491.

  6. Cervelli V, Garcovich S, Bielli A, Cervelli G, Curcio BC, Scioli MG et al. The effect of autologous activated platelet rich plasma (AA-PRP) injection on pattern hair loss: clinical and histomorphometric evaluation. Bio Med Res Int. 2014; 2014: 760709.

  7. Li M, Marubayashi A, Nakaya Y, Fukui K, Arase S. Minoxidil-induced hair growth is mediated by adenosine in cultured dermal papilla cells: possible involvement of sulfonylurea receptor 2B as a target of minoxidil. J Invest Dermatol. 2001; 117: 1594-1600.

  8. Hu R, Xu F, Sheng Y, Qi S, Han Y, Miao Y et al. Combined treatment with oral finasteride and topical minoxidil in male androgenetic alopecia: a randomized and comparative study in Chinese patients. Dermatol Ther. 2015; 28: 303-308.

  9. Adil A, Godwin M. The effectiveness of treatments for androgenetic alopecia: a systematic review and meta-analysis. J Am Acad Dermatol. 2017; 77: 136-141.e5.

  10. Kumaresan M, Mysore V. Controversies in hair transplantation. J Cutan Aesthet Surg. 2018; 11: 173-181.

  11. Darwin E, Heyes A, Hirt PA, Cao WT, Jimenez JJ. Low-level laser therapy for the treatment of androgenic alopecia: a review. Lasers Med Sci. 2018; 33: 425-434.

  12. Marx RE. Platelet-rich plasma (PRP): what is PRP and what is not PRP? Implant Dent. 2001; 10: 225-228.

  13. Li ZJ, Choi HI, Choi DK, Sohn KC, Im M, Seo YJ et al. Autologous platelet-rich plasma: a potential therapeutic tool for promoting hair growth. Dermatol Surg. 2012; 38: 1040-1046.

  14. Alves R, Grimalt R. A review of platelet-rich plasma: history, biology, mechanism of action, and classification. Skin Appendage Disord. 2018; 4: 18-24.

  15. Mecklenburg L, Tobin DJ, Müller-Rover S, Handjiski B, Peters EM et al. Active hair growth (anagen) is associated with angiogenesis. J Invest Dermatol. 2000; 114: 909-916.

  16. Goldman BE, Fisher DM, Ringler SL. Transcutaneous PO2 of the scalp in male pattern baldness: a new piece to the puzzle. Plast Reconstr Surg. 1996; 97: 1109-1116.

  17. Li W, Enomoto M, Ukegawa M, Hirai T, Sotome S, Wakabayashi Y et al. Subcutaneous injections of platelet-rich plasma into skin flaps modulate proangiogenic gene expression and improve survival rates. Plast Reconstr Surg. 2012; 129: 858-866.

  18. Takikawa M, Nakamura S, Nakamura S, Ishirara M, Kishimoto S, Sasaki K et al. Enhanced effect of platelet-rich plasma containing a new carrier on hair growth. Dermatol Surg. 2011; 37: 1721-1729.

  19. Stevens J, Khetarpal S. Platelet-rich plasma for androgenetic alopecia: a review of the literature and proposed treatment protocol. Int J Womens Dermatol. 2018; 5: 46-51.

  20. Gkini MA, Kouskoukis AE, Tripsianis G, Rigopoulos D, Kouskoukis K. Study of platelet-rich plasma injections in the treatment of androgenetic alopecia through an one-year period. J Cutan Aesthetic Surg. 2014; 7: 213-219.

  21. Gentile P, Garcovich S. Systematic review of platelet-rich plasma use in androgenetic alopecia compared with minoxidil, finasteride, and adult stem cell-based therapy. Int J Mol Sci. 2020; 21: 2702.




2020     |     www.medigraphic.com